Misdiagnosed male breast cancer with an unknown primary tumor: A case report

Wenwu Wang, Lang Chen, Xuenong OuyangOncology 2014 · DOI

TL;DR

This case report highlights the diagnostic challenges of male breast cancer (MBC) with an unknown primary tumor, emphasizing how it can be misdiagnosed as secondary lymph node cancer. The paper underscores the critical role of thorough pathological and immunohistochemical analysis in accurately diagnosing MBC, even when the primary tumor is elusive.

What Problem Does This Paper Address?

Male breast cancer (MBC) is a rare condition, accounting for only about 1% of all breast cancer cases. This rarity, coupled with its often atypical presentation (e.g., painless masses in the armpit rather than the breast itself), leads to a significant delay in diagnosis and treatment. A particularly challenging subset is MBC with an unknown primary tumor, where the initial breast lesion cannot be detected through physical examination or standard imaging. This scenario is prone to misdiagnosis, often being mistaken for metastatic cancer from another, unknown primary site, as seen in this case where it was initially diagnosed as secondary lymph node cancer. The paper aims to shed light on such a case to improve clinical awareness and diagnostic accuracy for MBC.

Methods

The paper presents a detailed case study of a 58-year-old male. The diagnostic process involved:

  • Initial Clinical Examination and Biopsy: The patient presented with an armpit mass, which underwent biopsy and initial pathological examination.
  • Chemotherapy: Based on the initial diagnosis, the patient received chemotherapy.
  • Re-evaluation and Repeat Biopsy Analysis: Due to disease progression and persistent diagnostic uncertainty, a multidisciplinary consultation was held. This led to a re-examination of the initial pathological sections and paraffin blocks.
  • Immunohistochemistry (IHC): IHC analysis was performed on the biopsy specimens to identify specific cellular markers.
  • Imaging: Mammography and PET-CT scans were utilized to locate a primary tumor.
  • Surgical Intervention: A modified radical mastectomy of the left breast was performed.

The core methodological contribution lies in the re-evaluation of pathological findings and the crucial role of immunohistochemistry in overturning the initial misdiagnosis.

Datasets

Not discussed in the paper. This is a single case report, not a study involving a dataset of multiple patients or a benchmark.

Key Insights and Ideas

  • The "Unknown Primary" Challenge: MBC with an unknown primary tumor is a significant diagnostic hurdle, often leading to misdiagnosis as metastatic cancer from another site.
  • Armpit Mass as a Red Herring: A palpable mass in the armpit can be the initial presentation of MBC, even without a detectable breast lesion, and can be mistaken for lymph node metastasis from an unknown source.
  • The Indispensable Role of Pathology and IHC: When clinical and imaging findings are inconclusive or contradictory, a thorough re-examination of pathological specimens, particularly with immunohistochemistry, is paramount for accurate diagnosis. IHC can reveal markers indicative of breast origin even when the primary tumor is not apparent.
  • Potential for Primary Tumor Disappearance: The paper suggests that primary tumors in MBC might, in some instances, disappear subsequent to chemotherapy, further complicating diagnosis.
  • Delayed Diagnosis Impacts Prognosis: The rarity and diagnostic challenges of MBC contribute to delayed treatment, which generally leads to a worse prognosis compared to female breast cancer.

Key Results

  • The patient was initially misdiagnosed with secondary lymph node cancer with an unknown primary tumor.
  • Subsequent re-examination of pathological sections and immunohistochemistry revealed the mass to be invasive ductal carcinoma, originating from the breast.
  • Despite extensive imaging (mammography, PET-CT), no primary breast tumor was identified.
  • Following a modified radical mastectomy, no residual cancer was found in the breast specimen, but metastatic cancer in the axillary lymph nodes was confirmed.
  • The patient's condition improved with adjuvant chemotherapy and radiotherapy after the correct diagnosis and surgery.

Limitations and Future Work

Limitations:

  • Single Case Report: The findings are based on a single patient, limiting generalizability.
  • Elusive Primary Tumor: The primary breast tumor remained undetected throughout the diagnostic and surgical process, highlighting a persistent challenge in some MBC cases.
  • Lack of Prospective Data: The paper notes a general lack of prospective, randomized clinical trials for MBC treatment.

Future Work:

  • The authors emphasize the need for increased clinical awareness and attention to MBC, especially in cases presenting with axillary lymphadenopathy without a clear primary breast lesion.
  • They advocate for a multidisciplinary approach and rigorous pathological evaluation, including IHC, to guide diagnosis and treatment.
  • The paper implicitly calls for more research into the specific characteristics and management of MBC, particularly the "unknown primary" subtype.
  • Clinicians are encouraged to question initial diagnoses if treatment is ineffective and diagnostic results are not absolutely clear, relying on a consistent correlation between pathology reports and clinical manifestations.

Summary updated

Abstract

Compared with female breast cancer, male breast cancer (MBC) has an extremely low morbidity, later staging and fewer breast tissues. The lumps are easier to invade in the center and the majority of the cases are positive for metastatic lymph node, with the typical clinical manifestation as a painless mass in partial breast. MBC with an unknown primary tumor is rare and is often prone to misdiagnosis, resulting in a delay in correct treatment. Such a case is extremely significant for clinical reference. The current study presents a 58-year-old male who developed a painless mass in the left armpit and received armpit mass biopsy and pathological examination which showed glandular cancer, with a high possibility of mammary primary tumor. The patient was administered four cycles of paclitaxel plus oxaliplatin chemotherapy. However, three months later, the patient identified novel disseminated lymph nodes in the left armpit. The initial pathological section and paraffin blocks were re-examined and the patient was finally diagnosed with breast invasive ductal carcinoma based on the metastases pathology and immunohistochemical examination. No breast mass was found on physical examination of the patient and the tumor markers, including cancer antigen 125 and carcinoembryonic antigen, were normal. No primary tumors were observed in the mammography and PET-CT and the primary tumor was not found following the left breast modified radical mastectomy.
BibTeX
@inproceedings{wang2014misdiagnosed,
  author = {Wenwu Wang and Lang Chen and Xuenong Ouyang},
  title = {{Misdiagnosed male breast cancer with an unknown primary tumor: A case report}},
  booktitle = {Oncology},
  year = {2014},
  doi = {10.3892/ol.2014.2111},
}
Figure